Head to Head Survey: Nyxoah (NASDAQ:NYXH) versus Schrodinger (NASDAQ:SDGR)

Nyxoah (NASDAQ:NYXH) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

79.1% of Schrodinger shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Nyxoah and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Schrodinger	-40.61%	-30.85%	-15.32%

Valuation and Earnings

This table compares Nyxoah and Schrodinger”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33 million	5.30	-$101.92 million	($2.48)	-0.63
Schrodinger	$255.87 million	4.21	-$103.26 million	($1.41)	-10.35

Nyxoah has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Nyxoah and Schrodinger, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
Schrodinger	1	4	4	0	2.33

Nyxoah presently has a consensus target price of $7.67, suggesting a potential upside of 394.62%. Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 38.70%. Given Nyxoah’s higher probable upside, analysts clearly believe Nyxoah is more favorable than Schrodinger.

Risk & Volatility

Nyxoah has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Summary

Schrodinger beats Nyxoah on 10 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.